Lenvatinib enhances T cell immunity and the efficacy of adoptive chimeric antigen receptor-modified T cells by decreasing myeloid-derived suppressor cells in cancer
Mengmeng Lü(Xuzhou Medical College), Qing Zhang(South China University of Technology), Xiaolei Hu(Shanghai Jiao Tong University), Junnian Zheng(Xuzhou Medical College), Chao Huang(Xuzhou Medical College), Bixi Wang(Xuzhou Medical College), Xiaohuan Wei(Xuzhou Medical College), Zhen Li(Tongji Hospital), Xiaokang Zhang(Center for Excellence in Brain Science and Intelligence Technology), Wei Zhang(Capital Medical University), Heng Xu(Xuzhou Medical College), Shishuo Sun(Xuzhou Medical College), Xinhui Feng(Xuzhou Medical College), Xiaoge Gao(Xuzhou Medical College)
Cited by 50
Related Papers
A new class of highly potent, broadly neutralizing antibodies isolated from viremic patients infected with dengue virus
|Nature Immunology|2014|497
Cancer drug delivery in the nano era: An overview and perspectives
|Oncology Reports|2017|399
Decorin is a pivotal effector in the extracellular matrix and tumour microenvironment
|Oncotarget|2018|217
DNA damage response – A double-edged sword in cancer prevention and cancer therapy
|Cancer Letters|2014|189
Combination Therapy with EpCAM-CAR-NK-92 Cells and Regorafenib against Human Colorectal Cancer Models
|Journal of Immunology Research|2018|152